Alcon LADARWave Will Be First “Custom” LASIK PMA To Reach Panel
This article was originally published in The Gray Sheet
Executive Summary
Alcon's LADARWave in-situ keratomileusis (LASIK) wavefront laser system will be the first "custom LASIK" system to reach FDA panel review, according to the company. The agency's 1Ophthalmic Devices Advisory Panel will review the firm's PMA at its Aug. 1 meeting in Gaithersburg, Maryland
You may also be interested in...
Alcon “Custom” LASIK Endorsed By Panel; Patient Education Urged
Patients undergoing "custom" wavefront-guided LASIK vision correction surgery must be made aware that the procedure is not a panacea for all their optical aberrations and not assume that it will result in better vision than traditional correction, according to FDA's Opthalmic Devices advisory panel
Alcon “Custom” LASIK Endorsed By Panel; Patient Education Urged
Patients undergoing "custom" wavefront-guided LASIK vision correction surgery must be made aware that the procedure is not a panacea for all their optical aberrations and not assume that it will result in better vision than traditional correction, according to FDA's Opthalmic Devices advisory panel
Alcon Entering Refractive Laser Surgery Market Via $890 Mil. Summit Buy
Alcon Labs' $890 mil. cash purchase of ophthalmic excimer laser manufacturer Summit Autonomous will place it on a level playing field with competitor Bausch & Lomb, which already competes in the eye laser market. The definitive deal was announced May 26.